Issuance of convertible equity warrants by way of preferential issue (“Preferential Issue”)
As filed · Outcome of Board Meeting
CapitalWatchMajormateriality 76 out of 100
What happened
FactIssuance of convertible equity warrants by way of preferential issue (“Preferential Issue”). Preferential Issue of up to 11,70,000 (Eleven Lakh Seventy Thousand) fully convertible equity. warrants (“Warrants”), each carrying a right exercisable by the warrant holder to subscribe to one (1).
Why it matters
CapitSignal interpretationShares are issued to named investors at a set price, diluting existing holders and changing who sits on the register.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedEarlierQ1 FY27
EBITDA margins stood at almost 30%, improving by 810 bps Y-o-Y.
NowQ1 FY27
Consolidated EBITDA for Q1 of FY27 stood at INR54 crores, growing by a robust 87% on a Y-o-Y basis.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved 190.00%.confidence 60%
Watch next
Fact- Who the allottees are
- Issue price versus market price
- Lock-in period on the new shares
- Based on the current business outlook and execution visibility, we expect the revenue growth of approximately (management committed by FY27)
- FY’27. So, next year, FY’27, we feel that margin when we get to about 18%, 20% to 22% kind of a number should (management committed by FY27)
Evidence
- Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on January 07, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- PREFERENTIAL_ALLOTMENT base 66; +2 corroborating keywords; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%